Changes in cognitive symptoms after a buspirone-melatonin combination treatment for Major Depressive Disorder

Journal of Psychiatric Research

Volumn 68, Issue , 2015, Pages 392-396

  Targum, Steven D ^a   Wedel, Pamela C ^b   Fava, Maurizio ^c,d  

^a Clintara LLC   (United States)

^b BrainCells Inc   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d NONE   (United States)

Author keywords

Anti depressant treatment; Cognition; CPFQ; Depression

Indexed keywords

BUSPIRONE; MELATONIN; PLACEBO; ANTIOXIDANT; SEROTONIN AGONIST;

ANTIDEPRESSANT ACTIVITY; ARTICLE; COGNITION; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DSM-IV-TR; EFFECT SIZE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE; ACUTE DISEASE; COGNITION DISORDERS; COMBINATION DRUG THERAPY; COMPLICATION; DEPRESSIVE DISORDER, MAJOR; OUTCOME ASSESSMENT;

ACUTE DISEASE; ANTIOXIDANTS; BUSPIRONE; COGNITION DISORDERS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMANS; MELATONIN; OUTCOME ASSESSMENT (HEALTH CARE); SEROTONIN RECEPTOR AGONISTS;

EID: 84937969854     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2015.04.024     Document Type: Article

References (27)

1. American Psychiatric Association Diagnostic and statistical manual of mental disorders 2013, American Psychiatric Publishing, Arlington, VA. 5th ed.
2. Austin M.P., Mitchell P., Goodwin G.M. Cognitive deficits in depression: possible implications for functional neuropathology. Br J Psychiat 2001, 178:200-204.
3. Conradi H.J., Ormel J., de Jonge P. Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychol Med 2011, 41(6):1165-1174.
4. Fava M., Graves L.M., Benazzi F., Scalia M.J., Iosifescu D.V., Alpert J.E., et al. Across-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. JClin Psychiat 2006, 67(11):1754-1759.
5. Fava M., Iosifescu D.V., Pedrelli P., Baer L. Reliability and validity of the MGH Cognitive and Physical Functioning Questionnaire (CPFQ). Psychother Psychosom 2009, 78:91-97.
6. Fava M., Targum S.D., Nierenberg A.A., Bleicher L.S., Carter T.A., Wedel P.C., et al. An exploratory study of combination buspirone and melatonin SR in Major Depressive Disorder (MDD): a possible role for neurogenesis in drug discovery. JPsychiat Res 2012, 46:1553-1563.
7. Fava M., Lophaven S., Olsen C. Effects of vortioxetine on cognitive symptoms of Major Depressive Disorder (MDD). 29th World Congress of Neuropsychopharmacology, Vancouver BC June 23, 2014.
8. Gotlib I.H., Joormann J. Cognition and depression: current status and future directions. Annu Rev Clin Psychol 2010, 6:285-312.
9. Guy W. ECDEU assessment manual for psychopharmacology 1976, 534-537. DHEW Publication ADM, 76-338.
10. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959, 32:50-55.
11. Kircanski K., Joorman J., Gotlib I.H. Cognitive aspects of depression. Wiley Interdiscip Rev Cogn Sci 2012, 3(3):301-313.
12. Kirsch I., Sapirstein G. Listening to prozac but hearing placebo: a meta-analysis of antidepressant medication. Prev Treat 1998, 1. Article 0002a. http://journals.apa.org/prevention/volume1/pre0010002a.html.
13. Lê S., Josse J., Husson F. FactoMineR: an R package for multivariate analysis. JStat Softw 2008, 25(1):1-18.
14. Malberg J.E., Eisch A.J., Nestler E.J., Duman R.S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. JNeurosci 2000, 20(24):9104e10.
15. Mcintyre R.S., Cha D.S., Soczynska J.K., Woldeyohannes H.O., Gallaugher L.A., Kudlow P., et al. Cognitive deficits and functional outcomes in Major Depressive Disorder: determinants, substrates, and treatment interventions. Depress Anxiety 2013, 30(6):515-527.
16. McIntyre R.S., Lophaven S., Olsen C.K. Arandomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol 2014, 17:1557-1567.
17. Nierenberg A.A., Keefe B.R., Leslie V.C., Alpert J.E., Pava J.A., Worthington J.J., et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. JClin Psychiatry 1999, 60:221-225.
18. Pedrelli P., Baer L., Iosefescu D.V., Fava M. Relationship between residual symptoms of depression and self-reported cognitive impairment. CNS Spectrums 2010, 15(1):46-51.
19. R Core Development Team R: a language and environment for statistical computing 2014, R Foundation for Statistical Computing, Vienna, Austria.
20. Roca M., Monzon S., Vives M., Lopez-Navarro E., Garcia-Toro M., Vicens C., et al. Cognitive function after clinical remission in patients with melancholic and non-melancholic depression: a 6 month follow-up study 2014, 171C:85-92.
21. Rush A.J., Giles D.E., Schlesser M.A., Fulton C.L., Weissenburger Burns C. The Inventory for Depressive Symptomatology (IDS): preliminary findings. Psychiat Res 1986, 18(1):65-87.
22. Rush A.J., Trivedi M.H., Ibrahim H.M., Carmody T., Arnow B., Klein D.N., et al. The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003, 54(5):573-583.
23. Sahay A., Hen R. Adult hippocampal neurogenesis in depression. Nat Neurosci 2007, 10(9):1110e5.
24. Sahay A., Scobie K.N., Hill As., O'Carroll C.M., Kheirbek M.A., Burghardt N.S., et al. Increasing adult hippocampal neurogenesis is sufficient to improve pattern separation. Nature 2011, 472(7344):446-470.
25. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. JClin Psychiatry 1998, 59(Suppl.20):22-33.
26. Stordal K.I., Lundervold A.J., Mykletun A., Asbjornsen A., Biringer E., Egeland J., et al. Frequency and characteristics of recurrent major depressed patients with unimpaired executive functions. World J Biol Psychiatry 2005, 6(1):36-44.
27. Targum S.D., Wedel P.C., Bleicher L.S., Busner J., Daniel D.S., Robinson J., et al. Acomparative analysis of centralized, site-based, and patient ratings in a clinical trial of Major Depressive Disorder. J.Psychiatric Res 2013, 47:944-954.